Abound Bio

Abound Bio is a biotechnology company with a mission to develop innovative antibody-based therapeutics to address unmet medical needs in cancer and infectious diseases. Led by renowned experts in therapeutic antibodies, infectious diseases, and cancer, the company has a successful track record in developing biotherapeutics, licensing, and partnerships. In 2022, Abound Bio was acquired by Galapagos, a fully integrated biotechnology company aiming to transform patient outcomes through groundbreaking science and innovation. As a result of the acquisition, all updates, news, and insights will now be shared on the Galapagos’ page, while the Abound Bio page will serve for historical purposes. For further details on the acquisition, refer to the press release from June 22, 2022: Press Release. Abound Bio's focus on pioneering therapies demonstrates its potential to make significant contributions to the biotechnology, healthcare, and health and wellness industries.